The remaining cornerstones of antihypertensive therapy — mechanisms, agents, adverse effects, and evidence
Calcium channel blockers and diuretics together represent two of the four pillars of the evidence-based framework for hypertension management. Alongside ACE inhibitors and angiotensin receptor blockers, these two classes form the foundation of initial therapy and combination regimens for the majority of hypertensive patients.1,2
Calcium channel blockers are among the most versatile antihypertensive agents available, with a broad efficacy profile across demographic groups, well-established indications in angina and certain arrhythmias, and a safety record supported by decades of large outcome trials. Diuretics, particularly thiazide and thiazide-like agents, were the first class shown to reduce cardiovascular mortality in hypertension and remain essential both as monotherapy and as partners in combination regimens.
Understanding the mechanistic distinctions within each class, their pharmacokinetic profiles, and the clinical evidence base is essential for rational prescribing across the full spectrum of hypertensive patients.
Mechanism, subclass distinctions, individual agents, and clinical applications
Calcium channel blockers inhibit voltage-gated L-type (long-lasting) calcium channels in vascular smooth muscle and cardiac tissue. L-type channels are the principal pathway for calcium entry that triggers smooth muscle contraction and regulates cardiac automaticity, conduction, and contractility.1,2
The downstream consequences of L-type channel blockade include relaxation of vascular smooth muscle with a reduction in total peripheral resistance, dilation of coronary and peripheral arterioles, slowing of cardiac conduction at the sinoatrial and atrioventricular nodes, and a reduction in myocardial contractility. The latter two effects are relevant only to non-dihydropyridine agents.
The critical pharmacological distinction within the class is tissue selectivity, which determines whether an agent acts predominantly on vascular smooth muscle (dihydropyridines) or on both vascular and cardiac tissue (non-dihydropyridines).
Dihydropyridines bind preferentially to the inactivated state of vascular L-type calcium channels and have high vascular-to-cardiac selectivity. They produce potent peripheral and coronary vasodilation with minimal direct cardiac effects at therapeutic doses.1,2 Vasodilation may cause reflex sympathetic activation and reflex tachycardia, a phenomenon that is more pronounced with short-acting agents and substantially attenuated with long-acting formulations or when a beta-blocker is added. Peripheral edema is common and reflects preferential arteriolar dilation increasing capillary hydrostatic pressure in dependent tissues.
Short-acting (immediate-release) nifedipine is contraindicated for hypertension management. Abrupt vasodilation produces reflex tachycardia and has been associated with an increased risk of adverse cardiovascular outcomes. Only long-acting formulations (GITS, XL, CC) are appropriate for hypertension.
Non-dihydropyridines bind preferentially to the activated state of L-type calcium channels in cardiac tissue and have approximately equal effects on vascular smooth muscle and cardiac tissue. Their cardiac actions, including negative chronotropy, negative dromotropy, and negative inotropy, make them distinct agents from a clinical standpoint, despite sharing the same primary mechanism of calcium channel blockade.1,2
The adverse effect profiles of dihydropyridine and non-dihydropyridine agents differ substantially and reflect their differing tissue selectivity.
Peripheral edema is the most clinically significant adverse effect of dihydropyridine agents, occurring in 5–30% of patients in a dose-dependent manner. The mechanism is preferential arteriolar dilation, which increases capillary hydrostatic pressure in dependent tissues without compensatory venodilation. This is not sodium-mediated volume overload. Adding a diuretic has limited efficacy against this form of edema. Adding a renin-angiotensin-aldosterone system (RAAS) inhibitor is more effective, as RAAS inhibition causes efferent arteriolar and venous dilation, reducing capillary hydrostatic pressure; this pharmacological interaction partly explains the superiority of the calcium channel blocker plus RAAS inhibitor combination demonstrated in the ACCOMPLISH trial.5 Reflex tachycardia and flushing are more common with short-acting formulations and generally resolve with long-acting agents.
Non-dihydropyridine adverse effects reflect their cardiac actions: bradycardia from sinoatrial node suppression, variable degrees of atrioventricular block, and reduced myocardial contractility that is clinically important in the setting of reduced systolic function. Constipation occurs in up to 25% of patients receiving verapamil, attributable to calcium channel inhibition in intestinal smooth muscle.
Verapamil and diltiazem are contraindicated in heart failure with reduced ejection fraction, pre-existing bradycardia or high-degree atrioventricular block (without pacemaker), concurrent beta-blocker use (risk of complete heart block and asystole), Wolff-Parkinson-White syndrome with atrial fibrillation, and hypotension.
In patients who identify as Black, calcium channel blockers are among the most effective antihypertensive agents, reflecting the low-renin, volume-dependent physiology that is more prevalent in this population. The ALLHAT trial demonstrated equivalence for amlodipine across racial groups for the primary cardiovascular endpoint and superiority over lisinopril for stroke prevention specifically in Black patients.4
In pregnancy, long-acting nifedipine is one of the recommended agents for chronic hypertension and for acute severe hypertension. A well-established safety record exists at therapeutic doses, and no teratogenic effects have been identified. Oral nifedipine is used as an alternative to intravenous labetalol or hydralazine for acute severe hypertension in pregnancy.
In isolated systolic hypertension in elderly patients, long-acting dihydropyridine agents are among the most effective options. The Syst-Eur trial demonstrated that nitrendipine reduced stroke by approximately 42% in this population.7
Thiazide, loop, and potassium-sparing agents — mechanisms, agents, metabolic effects, and clinical roles
Diuretics lower blood pressure through two temporally distinct mechanisms. The acute effect is natriuresis and volume depletion, reducing preload and cardiac output. With chronic use, total peripheral resistance falls through a mechanism that is not completely understood but may involve reduced vascular smooth muscle sodium content and decreased reactivity to vasoconstrictors. Volume effects normalize over weeks, but the blood pressure reduction is maintained.
These agents are the most extensively studied antihypertensive diuretics, with decades of outcome trial evidence establishing their role as first-line agents.1,2 Their primary mechanism is inhibition of the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, producing natriuresis, chloruresis, mild potassium wasting, and mild hypomagnesemia. A notable feature is paradoxical enhancement of calcium reabsorption in the distal convoluted tubule, which is clinically useful in calcium nephrolithiasis and potentially protective against osteoporosis-related fractures.
| Agent | Dose | Half-life | Key Feature |
|---|---|---|---|
| Hydrochlorothiazide | 12.5–50 mg once daily | ~10–12 h | Most widely used; BP effect plateaus above 25 mg; inferior 24-h coverage vs chlorthalidone |
| Chlorthalidone | 12.5–25 mg once daily | ~40–60 h | Preferred thiazide-like agent; superior 24-h BP control; ALLHAT, SHEP landmark trials4,9 |
| Indapamide | 1.25–2.5 mg once daily | ~14–18 h | Additional vascular effects beyond NCC inhibition; favorable metabolic profile; retains efficacy at lower glomerular filtration rates; PROGRESS, HYVET trials10,11 |
Current ACC/AHA guidelines and expert opinion favor chlorthalidone over hydrochlorothiazide as the thiazide of choice for hypertension, based on its longer half-life, superior 24-hour blood pressure control, and stronger outcome trial evidence.1,8
Hypokalemia occurs in approximately 10–30% of patients on standard doses and results from increased sodium delivery to the collecting duct, which stimulates aldosterone-mediated potassium secretion. Clinically significant hypokalemia may increase the risk of ventricular arrhythmias, particularly in patients receiving digoxin or with pre-existing heart disease. Serum potassium should be checked within 2–4 weeks of initiation, with dose changes, and annually thereafter.
Hypomagnesemia co-occurs with hypokalemia. Magnesium depletion impairs renal potassium conservation, and correcting magnesium is often necessary to effectively correct potassium.
Hyperuricemia and gout may result from reduced uric acid excretion through competition for tubular secretion and from volume contraction increasing proximal tubular urate reabsorption. Asymptomatic hyperuricemia alone is not a contraindication. When thiazide plus RAAS inhibitor combination therapy is used in a patient with gout, losartan is the preferred RAAS agent given its modest uricosuric effect.
Glucose intolerance and new-onset diabetes are dose-dependent adverse effects of thiazide diuretics, more prominent than with ACE inhibitors, ARBs, or calcium channel blockers.3 The effect is most pronounced at hydrochlorothiazide doses above 25 mg per day. The mechanism involves potassium-mediated membrane hyperpolarization impairing insulin secretion, compounded by angiotensin II upregulation reducing insulin sensitivity. Chlorthalidone at 12.5–25 mg has a more modest glucose effect. Indapamide has the most favorable metabolic profile among thiazide-like agents. Thiazide-associated new-onset diabetes does not appear to carry the same cardiovascular risk as idiopathic type 2 diabetes in the context of otherwise well-controlled blood pressure.1
Hyponatremia occurs most commonly in elderly women and can be severe. The mechanism is enhanced free water retention relative to sodium loss, driven by volume depletion-stimulated antidiuretic hormone release. Chlorthalidone carries higher hyponatremia risk than hydrochlorothiazide due to its longer half-life. High-risk patients should be monitored carefully, particularly in the early weeks of therapy.
Loop diuretics inhibit the sodium-potassium-2-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, the segment responsible for reabsorbing approximately 25% of filtered sodium. Loop diuretics are the most potent diuretics available. Unlike thiazides, loop diuretics increase urinary calcium excretion.2
Loop diuretics are not first-line antihypertensive agents in patients with preserved renal function. Their primary antihypertensive role is in patients with stage 4–5 chronic kidney disease (estimated glomerular filtration rate below approximately 30 mL/min/1.73m²), where thiazide efficacy is markedly reduced. They are also used for volume control in heart failure complicating hypertension and in edematous states generally.
Furosemide has variable oral bioavailability (10–100%, averaging approximately 50%) and a short duration of action requiring twice-daily dosing. Torsemide has approximately 80% oral bioavailability, a more predictable pharmacokinetic profile, and is suitable for once-daily dosing. The TRANSFORM-HF trial (2023) did not demonstrate a mortality advantage for torsemide over furosemide in acute decompensated heart failure, though torsemide's pharmacological advantages remain clinically relevant for outpatient management.
These agents act in the collecting duct to reduce potassium excretion while maintaining modest natriuresis, and are used primarily as adjuncts to potassium-wasting diuretics or as targeted therapy in specific conditions.2
Spironolactone is a competitive mineralocorticoid receptor antagonist that blocks aldosterone-mediated sodium channel transcription in collecting duct principal cells. It is particularly effective in low-renin, volume-dependent hypertension and is the drug of choice for bilateral adrenal hyperplasia causing primary aldosteronism. In the PATHWAY-2 trial, spironolactone was superior to both bisoprolol and doxazosin as a fourth-line agent for resistant hypertension.12 Hyperkalemia is its most important adverse effect, with risk amplified by concurrent chronic kidney disease, RAAS inhibitor use, and diabetes. Anti-androgenic effects, including gynecomastia, menstrual irregularities, and erectile dysfunction, result from binding to progesterone and androgen receptors in addition to the mineralocorticoid receptor.
Eplerenone is a selective mineralocorticoid receptor antagonist that does not bind androgen or progesterone receptors, avoiding the sex hormone adverse effects of spironolactone. It is approximately 40–50 times less potent than spironolactone at the mineralocorticoid receptor. In the EMPHASIS-HF trial, eplerenone added to standard heart failure therapy in patients with mild symptoms reduced cardiovascular mortality and heart failure hospitalizations by 37%.13
Finerenone is a non-steroidal mineralocorticoid receptor antagonist with distinct pharmacology from the steroidal agents. In the FIDELIO-diabetic kidney disease (DKD) trial, finerenone reduced chronic kidney disease progression and cardiovascular events in patients with type 2 diabetes, chronic kidney disease, and albuminuria on background RAAS inhibition.14 It carries lower hyperkalemia risk than steroidal agents at antifibrotic doses and has no sex hormone side effects.
Amiloride and triamterene directly block epithelial sodium channels in the collecting duct through a mechanism independent of aldosterone. Amiloride is the preferred agent in Liddle syndrome, a rare condition of constitutively active epithelial sodium channels. Triamterene is poorly soluble and may crystallize in urine, rarely causing nephrolithiasis; it should be avoided in patients with a history of kidney stones or significant chronic kidney disease.
Evidence-based pairing and combinations to avoid
Single-pill combination therapy improves adherence and is increasingly recommended as initial therapy for Stage 2 hypertension or high-risk patients.1,2
The calcium channel blocker plus RAAS inhibitor combination is physiologically synergistic: the calcium channel blocker causes arteriolar dilation, while the RAAS inhibitor blunts the reactive RAAS activation this induces and reduces calcium channel blocker-associated peripheral edema through venous and efferent arteriolar dilation. The ACCOMPLISH trial demonstrated that benazepril plus amlodipine was significantly superior to benazepril plus hydrochlorothiazide in reducing cardiovascular events (a 20% relative risk reduction) despite similar blood pressure reduction in both groups.5 This result shifted practice toward the calcium channel blocker plus RAAS inhibitor combination as the preferred dual regimen in high-risk patients.
The RAAS inhibitor plus thiazide combination works through complementary mechanisms: the diuretic activates the RAAS through volume depletion, which enhances RAAS inhibitor efficacy, while the RAAS inhibitor blunts the diuretic-induced hypokalemia and metabolic activation. This combination has decades of supporting evidence and is preferred when fluid retention is a concern.
Triple therapy with a calcium channel blocker, RAAS inhibitor, and thiazide diuretic simultaneously addresses all major blood pressure-regulating pathways and is the standard of care for hypertension uncontrolled on dual therapy.
Non-dihydropyridine CCB plus beta-blocker: risk of severe bradycardia, atrioventricular block, and asystole; this combination is contraindicated. Dual RAAS blockade (ACE inhibitor plus ARB): ONTARGET and VA NEPHRON-D established that this increases adverse effects without additional benefit. Thiazide plus loop diuretic: causes excessive natriuresis and volume depletion; appropriate only in severe diuretic-resistant states under specialist supervision.
Chronic kidney disease, heart failure, elderly patients, and diabetes mellitus
In chronic kidney disease with an estimated glomerular filtration rate of 30–60 mL/min/1.73m², thiazide and thiazide-like diuretics retain partial efficacy. Chlorthalidone and indapamide maintain better efficacy at lower glomerular filtration rates than hydrochlorothiazide. Loop diuretics are required as the primary diuretic when the estimated glomerular filtration rate falls below approximately 30 mL/min/1.73m². Potassium-sparing diuretics and mineralocorticoid receptor antagonists require particular caution in chronic kidney disease due to hyperkalemia risk; finerenone has the most favorable safety profile in this context.14
In heart failure complicating hypertension, loop diuretics are used for symptomatic volume overload. Aldosterone antagonists, either spironolactone or eplerenone, are guideline-directed medical therapy in heart failure with reduced ejection fraction. Thiazides are generally avoided in moderate-to-severe heart failure.
In elderly patients, thiazide and thiazide-like diuretics are highly effective and among the preferred agents for isolated systolic hypertension, as demonstrated in the SHEP and HYVET trials.9,11 The risk of hyponatremia, orthostatic hypotension, and electrolyte disturbance is higher in this population. Starting at the lowest effective dose is appropriate, and falls risk associated with orthostatic hypotension should be considered in the overall management plan.
In diabetes mellitus, thiazides at low doses are acceptable: hydrochlorothiazide 12.5–25 mg and chlorthalidone 12.5 mg have modest glucose effects at these doses. Higher doses increase the risk of glucose intolerance. Where possible, an ACE inhibitor or ARB plus calcium channel blocker is preferred as the primary combination in patients with diabetes, with a thiazide added as needed for additional blood pressure control. Indapamide has the most favorable metabolic profile among thiazide-like agents in this setting.